Quantcast

Hospital-based Point of Care Diagnostics: Products, Players and Outlook to 2017

October 29, 2013

Reportbuyer.com just published a new market research report: Hospital-based Point of Care Diagnostics: Products, Players and Outlook to 2017.

London (PRWEB) October 29, 2013

The market for POC diagnostic products used in a hospital setting was worth approximately US$2.9 billion in 2011 with sectors such as cardiac markers making double digit growth in the year. There is growing interest in the adoption of POC technologies, strong demand in emerging markets, and new products that enable POC testing for more applications are being introduced.

The benefits are clear. Hospital-based POC diagnostics offer healthcare providers an opportunity to improve the quality of patient care while saving time and reducing costs. A faster diagnosis can mean a faster medical intervention, potentially avoiding the need to admit a patient into hospital and the costs incurred as a result, while also freeing up that hospital bed.

It’s not all plain sailing. Concerns have been raised by laboratory professionals that the use of POC products by less skilled users may result in inaccurate diagnoses. This has strengthened resistance to the changes needed for POC products to be widely adopted. The counter argument is not helped by the lack of a wide clinical evidence base which proves POC diagnostics deliver lab-quality results and benefit from being convenient and cost-effective.

There are around 80 companies active in the hospital POC diagnostics market, although many are development-stage or have limited product portfolios. The market is currently dominated by Alere, Abbott, Radiometer, Roche and Siemens. Currently, Abbott, Radiometer, Roche and Siemens have strong positions in the markets for clinical chemistry and blood gas analysis; Abbott, Alere and Roche are leaders for POC cardiac marker testing; and Beckman Coulter, Quest Diagnostics, Horiba and Sysmex are key companies in POC haematology diagnostics.

This volume provides…

Market growth forecasts by sector to 2017

Directory of 80 companies with 16 detailed profiles

Detailed operating environment analysis

All major POC hospital-based testing technologies are covered

Haematology analysers

Blood Gas analysers

Electrolyte analysers

Cardiac markers

Multi-functional clinical chemistry analysers

Urinalysis

About the Author

This report has been researched and written by independent medical market analyst Joanne Maddox. For over 13 years she has played a pivotal role in tracking trends in medical device and equipment markets and companies. A former editor of Medical Device Companies Analysis she has also written The Global Advanced Wound Care Market to 2017; Advances in Molecular Imaging 2013; and, Telemonitoring: Challenges and Opportunities.

About the Publisher

For over 30 years Espicom Business Intelligence, a Business Monitor company, has been a leading provider of key medical device and technology data. Its experienced and knowledgeable authors are uniquely placed to produce this high-quality and thoroughly researched management report. Espicom is part of Business Monitor International.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 1

INTRODUCTION 2

POC Testing in a Hospital Setting 2

CURRENT MARKET DYNAMICS 4

Fig 1: POC Diagnostics in Relation to the IVD Market, 2011 4

Fig 2: Percentage of POC Diagnostics Market by Product, 2011 5

Regional Perspective 5

Fig 3: Professional POC Diagnostics Market by Region, 2011 6

Regulatory and Reimbursement Environment 6

CLIA Waiver 6

Hospital POC Testing Market 7

Hospital POC Testing Market by Product Type, 2007-2011 (US$ million) 8

Fig 4: Hospital POC Testing Market by Product Type, 2011 8

COMPETITIVE LANDSCAPE 9

Select POC Diagnostics Companies’ Sales, 2007-2011 (US$ million) 9

Market Leaders by Hospital POC Testing Product Type9

Merger and Acquisition Activity 10

Key Hospital POC Diagnostics Mergers and Acquisitions, 2008-2012 10

GROWTH DRIVERS, RESTRAINTS AND FUTURE OPPORTUNITIES 12

Clinical Utility and Accuracy 12

Connectivity 12

POC Diagnostics as a Disruptive Technology 13

POC Diagnostics and the Economy 14

Future Technology: Next-Generation POC Diagnostic Products 14

Lab-on-a-Chip Devices and Microfluidics 14

Detecting Hospital-Acquired Infections 15

Summary: Market Drivers, Restraints and Opportunities 16

FUTURE MARKET PROSPECTS 17

Hospital POC Testing Market by Product Type, 2011-2017E (US$ million) 17

Hospital POC Testing Market by Product Growth, 2008-2017E (%)18

Fig 5: Predicted Hospital POC Testing Market by Product, 2017 18

HOSPITAL POC TESTING PRODUCTS AND TECHNOLOGIES 19

MULTI-FUNCTIONAL CLINICAL CHEMISTRY ANALYSERS 19

Abaxis’ Piccolo xpress 19

Abbott’s i-STAT System 20

Alfa Wassermann’s ACE Clinical Chemistry Systems 21

Arkray’s SpotChem Systems 22

SpotChem Test Strips 22

Audit Diagnostics’ Liqui-Stat and DryLab Systems 22

DiaSys Diagnostic Systems’ InnovaStar 23

Horiba’s ABX Pentra Clinical Chemistry Analysers23

Ortho-Clinical Diagnostics’ VITROS DT60 II Chemistry System 23

Radiometer’s AQT90 FLEX Immunoassay Analyser 24

Randox Laboratories’ Evidence Multistat 24

Samsung’s LABGEO Clinical Chemistry Analysers 25

Tosoh Bioscience’s AIA Immunoassay Analysers25

POC BLOOD GAS/ELECTROLYTE ANALYSERS 27

Fig 6: POC Clinical Chemistry Market, 2007-2017E (US$ million) 27

Arkray’s SpotChem EL Electrolyte Analyser 28

Epocal’s epoc Blood Analysis System 28

Instrumentation Laboratory’s GEM Premier Products 29

tBili Assay 29

GEMweb Plus 29

ITC’s IRMA TRUpoint Blood Analysis System 30

ITC’s AVOXimeter Products 30

Nova Biomedical’s Critical Care Analysers 30

pHOx Ultra Blood Gas Analyser 30

Stat Profile pHOx 31

Stat Profile Critical Care Xpress 31

Nova Electrolyte/Chemistry Analysers 31

Hand-Held Analysers 32

OPTI Medical Systems’ Products 32

Radiometer’s Blood Gas Analysers 32

1st automatic32

ABL90 FLEX 33

ABL800 FLEX 33

Avoid Errors App 34

Roche’s cobas Blood Gas Analysers34

Siemens’ Blood Gas Analyser Range 35

RAPIDPoint Analysers35

RAPIDLab Analysers 36

RAPIDChem 744/754 Electrolyte and Lithium Testing 36

RAPIDComm Data Management and Connectivity Solution 36

Via Medical’s Products 37

POC HAEMATOLOGY AND HAEMOSTASIS PRODUCTS 38

Fig 7: Global POC Haematotolgy Market, 2007-2017E (US$ million) 38

Haematology Analysers 39

Beckman Coulter’s COULTER AC•T Series 39

Horiba’s Haematology Analysers 39

Samsung’s LABGEO HC10 41

Sysmex’ pocH-100i Haematology Analyser 41

POC Haemoglobin Systems 41

POC Analyser Accuracy42

Available Products 43

Arkray’s PocketChem BA Blood Ammonia Meters 48

Surgical Coagulation and Haemostasis Management 48

Akers Biosciences’ PIFA Heparin/PF4 and PIFA PLUSS Rapid Assays 49

Haemonetics’ TEG Thrombelastograph Hemostasis Analyzer 49

Medtronic’s HMS PLUS Haemostasis Management System 50

Pentapharm’s ROTEM delta 50

Sienco’s Sonoclot Coagulation & Platelet Function Analyzers 50

Platelet Function Assessment 51

Clinical Guidelines 51

Accumetrics’ VerifyNow System 52

Helena Laboratories’ Plateletworks System 53

POC CARDIAC MARKER TESTING 54

PROTECT Study 55

VISION Study 56

POC Testing 56

Gaining Clinical Evidence 57

Market Dynamics 58

Fig 6: Global POC Cardiac Marker Testing Market, 2007-2017E (US$ million) 58

POC Testing Products 59

Currently-Available Cardiac Marker POC Tests 59

POC URINALYSIS 69

Fig 9: Global POC Urinalysis Market, 2007-2017E (US$ million) 69

Key Urine Analysis Test Strips 70

Product Highlights 70

77 Elektronika’s DocUReader 2 and DocuReader 2 Pro 70

ACON Laboratories’ Mission Products 70

Arkray’s Products 71

Roche’s Products 71

Siemens’ Products 72

OTHER POC PRODUCTS 74

Labour and Delivery Testing 74

Alere’s Triage PLGF Assay 74

Amnisure International’s AmniSure ROM Test 75

Medix Biochemica’s Actim PROM and Actim Partus 75

Liver Function Testing 76

Exalenz Bioscience’s BreathID System 76

Infopia’s Pioneer POCT Liver Test Sensor76

Alere’s Triage NGAL Test 77

bioMérieux’ VIDAS B•R•A•H•M•S PCT Test 77

Magellan Biosciences’ LeadCare II System 78

Medix Biochemica’s Actim Pancreatitis 78

Products in Development 78

Akers Biosciences’ BreathPulmo Health Check and Breath Asthma Check 78

EMERGING TECHNOLOGIES 80

Applied Nanodetectors’ Sensor Array Platform 80

Atonomics’ Atolyzer 80

Ativa Medical’s POC System 81

Bio-AMD’s MPR81

Biosensia’s RapiPlex 82

Fiomi Diagnostics (Trinity Biotech) Forecast Technology 82

MagnaBioSciences’ MICT On-Site System 83

Micronics’ ABORhCard and ABO-XM Card 83

Molecular Vision 84

MycroLab 84

OPKO Health’s OPKO Diagnostics Platform 85

pes diagnosesysteme’ respons IQ 86

Philips’ Minicare 86

Radisens Diagnostics’ POC Platform 87

T2 Biosystems’ T2Dx System 88

T2Hemostasis Assay 89

Tyrian Diagnostics’ DiagnostIQ 89

Hospital-Acquired Infection Testing 90

Cepheid’s GeneXpert 91

Atlas Genetics’ POC System 92

BioFire Diagnostics’ FilmArray System 92

Immunexpress’ SeptiCyte Technology 93

Rheonix’ EncompassMDx Platform 94

HOSPITAL POC TESTING MANUFACTURERS 95

COMPANY DIRECTORY 95

SELECTED COMPANY PROFILES 100

Abaxis 100

Piccolo xpress 100

Financial Performance 101

Abaxis Operating Results, 2007-2012 (US$ million) 101

Abbott 102

Recent Key Events 102

i-STAT Point of Care Products 102

Alliance with Abaxis 104

Financial Performance 104

Abbott Point of Care Sales, 2010-2011 (US$ million) 104

Fig 10: Percentage of Abbott Point of Care Revenue by Region, 2011 104

Accumetrics 105

Recent Key Events 105

Fig 11: Accumetrics Revenue, 2005-2011 (US$ thousand) 105

VerifyNow System 106

Distribution Agreements 107

Akers Biosciences 108

Recent Key Events 108

Current Products 109

Research and Development 109

Current Alliances and Distribution Agreements110

Financial Performance 111

Akers Biosciences Operating Results, 2007-2011 (US$ thousands) 111

Fig 12: Percentage of Akers’ Revenue by Product Type, 2011 112

Alere 113

Recent Key Events 113

POC Cardiology Diagnostic Products 114

Women’s Health 116

RALS-Plus POC IT Solution 116

POC Mergers & Acquisitions 117

Current Alliances 119

Financial Performance 120

Alere – Operating Results, 2007-2011 (US$ million) 121

Fig 13: Percentage of Alere’s Revenue by Segment, 2011 121

Fig 14: Percentage of Alere’s Revenue by Region, 2011 121

Alere Professional Diagnostics Operating Results, 2007-2011 (US$ million) 122

Professional Diagnostics Net Sales & Services Revenue, 2007-2011 (US$ million) 122

Fig 15: Alere Professional Diagnostics Net Sales & Services Revenue by Product, 2011 122

Alere Consumer Diagnostics Operating Results, 2007-2011 (US$ million) 122

Arkray 124

Recent Key Events 124

POC Testing Products 124

Current Alliances 126

bioMérieux 127

bioNexia POC Tests 127

VIDAS Tests 127

Current Alliances 128

Financial Performance 129

bioMérieux – Operating Results, 2007-2011 (EUR million) 129

Fig 16: Percentage of bioMérieux’ Revenue by Product Type, 2011 130

Fig 17: Percentage of bioMérieux’s Revenue by Region, 2011 130

Horiba Medical 131

Recent Key Events 132

Haematology Analysers 132

ABX Pentra 400 Clinical Chemistry Analyser 134

Pentra C200 Clinical Chemistry Analyser 134

Financial Performance 134

Fig 18: Percentage of Horiba’s Revenue by Division, 2011 134

Horiba Medical – Operating Results, 2007-2011 (¥ million) 135

Fig 19: Percentage of Horiba Medical’s Revenue by Region, 2011 135

Fig 20: Percentage of Horiba Medical’s Revenue by Product Type, 2011 135

Instrumentation Laboratory137

Recent Key Events 137

POC Critical Care Diagnostics137

Purchasing Contracts 138

International Technidyne Corporation 139

Products 139

Current Alliances 140

Financial Performance 140

International Technidyne Operating Results, 2004-2009 (US$ million) 141

Fig 21: International Technidyne Revenue, 2000-2010 (US$ million) 141

Nova Biomedical 142

Critical Care Analysers 142

Hand-Held Analysers 143

Quest Diagnostics144

HemoCue Products 144

Litigation with EKF Diagnostics 146

Financial Performance 146

Quest Diagnostics – Operating Results, 2007-2011 (US$ million) 147

Quest Diagnostics – Sales and Earnings by Category, 2007-2011 (US$ million) 147

Fig 22: Quest Diagnostics – Revenue by Division, 2011 147

Radiometer (Danaher) 149

Recent Key Events 149

AQT90 FLEX Immunoassay Analyser 150

Blood Gas Analysers 150

AQURE POC Management System 152

RADIANCE IT system 152

Current Alliances 152

Financial Performance 153

Fig 23: Radiometer – Revenue by Region, 2010 153

Response Biomedical 154

Recent Key Events 154

RAMP System 155

Current Alliances 156

Financial Performance 157

Response Biomedical – Operating Results, 2007-2011 (C$ thousands) 157

Response Biomedical – Product Sales by Category, 2009-2011 (C$ thousands) 158

Fig 24: Response Biomedical – Product Sales by Category, 2011 158

Response Biomedical – Revenue by Region, 2009-2011 (C$ thousands) 158

Fig 25: Response Biomedical – Revenue by Region, 2011 159

Roche Diagnostics 160

Recent Key Events 160

Cardiac Testing Products 161

cobas Blood Gas Analysers 161

Urinalysis 162

cobas POC IT Solution 162

Current Alliances and Contracts 163

Financial Performance 163

Roche Diagnostics Operating Results, 2010-2011 (SFr million) 164

Fig 26: Roche Diagnostics – Revenue by Product Line, 2011 164

Fig 27: Roche Professional Diagnostics – Revenue by Region, 2011 164

Siemens Healthcare Diagnostics 166

Recent Key Events 166

Blood Gas Analyser Range 166

Urinalysis 168

Cardiology – Stratus CS Analyzer 169

RAPIDComm Data Management and Connectivity Solution 170

Current Alliances and Supply Contracts170

Financial Performance 170

APPENDICES 172

APPENDIX 1 – LIST OF ABBREVIATIONS 172

APPENDIX 2 – REPORT METHODOLOGY 173

Read the full report:

Hospital-based Point of Care Diagnostics: Products, Players and Outlook to 2017

http://www.reportbuyer.com/pharma_healthcare/diagnostics/hospital_based_point_care_diagnostics_products_players_outlook_2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11279579.htm


Source: prweb



comments powered by Disqus